AI Agents for Multimodal Oncology Diagnosis: Toward Transparent and Traceable Clinical Decision Support.

IF 2.6 Q2 ONCOLOGY
JMIR Cancer Pub Date : 2026-09-15 DOI:10.2196/103545
Liuyang Yang, Liyu Shan, Xiangmei Yao, Renbin Zhao, Zengzheng Li, Shuai Feng, Yajie Wang
{"title":"AI Agents for Multimodal Oncology Diagnosis: Toward Transparent and Traceable Clinical Decision Support.","authors":"Liuyang Yang, Liyu Shan, Xiangmei Yao, Renbin Zhao, Zengzheng Li, Shuai Feng, Yajie Wang","doi":"10.2196/103545","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer diagnosis depends on data from radiology, digital pathology, molecular profiling, laboratory testing, and longitudinal clinical records. AI performs well in selected tasks, but most systems remain narrow and disconnected from the iterative reasoning required in oncology. This Viewpoint defines an AI agent as a feedback-driven system that maintains task state, selects among governed tools, observes results, and revises its plan under explicit safety constraints. This definition separates agents from multimodal foundation models, retrieval-augmented generation, and fixed workflow automation. We organize the discussion across multimodal data collection, preprocessing, fusion and representation learning, and diagnostic decision support. We distinguished agent-level evidence, component- or infrastructure-level evidence, and prospective propositions throughout. Clinical translation will require resilient failure handling, guideline version control, prospective evaluation, computational and workflow feasibility, and clinician authority over final decisions. The near-term opportunity is therefore transparent and traceable clinical decision support rather than autonomous cancer diagnosis.</p>","PeriodicalId":45538,"journal":{"name":"JMIR Cancer","volume":"12 ","pages":"e103545"},"PeriodicalIF":2.6000,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624588/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/103545","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer diagnosis depends on data from radiology, digital pathology, molecular profiling, laboratory testing, and longitudinal clinical records. AI performs well in selected tasks, but most systems remain narrow and disconnected from the iterative reasoning required in oncology. This Viewpoint defines an AI agent as a feedback-driven system that maintains task state, selects among governed tools, observes results, and revises its plan under explicit safety constraints. This definition separates agents from multimodal foundation models, retrieval-augmented generation, and fixed workflow automation. We organize the discussion across multimodal data collection, preprocessing, fusion and representation learning, and diagnostic decision support. We distinguished agent-level evidence, component- or infrastructure-level evidence, and prospective propositions throughout. Clinical translation will require resilient failure handling, guideline version control, prospective evaluation, computational and workflow feasibility, and clinician authority over final decisions. The near-term opportunity is therefore transparent and traceable clinical decision support rather than autonomous cancer diagnosis.

多模式肿瘤诊断的人工智能代理:走向透明和可追溯的临床决策支持。
癌症诊断依赖于来自放射学、数字病理学、分子谱、实验室测试和纵向临床记录的数据。人工智能在选定的任务中表现良好,但大多数系统仍然狭窄,与肿瘤学所需的迭代推理脱节。这个观点将人工智能代理定义为一个反馈驱动的系统,它在明确的安全约束下维护任务状态,选择受治理的工具,观察结果并修改其计划。该定义将代理与多模态基础模型、检索增强生成和固定工作流自动化分离开来。我们组织讨论跨多模态数据收集,预处理,融合和表示学习,和诊断决策支持。我们区分了代理级证据、组件或基础设施级证据以及贯穿始终的前瞻性命题。临床翻译将需要有弹性的故障处理、指南版本控制、前瞻性评估、计算和工作流程可行性,以及临床医生对最终决定的权威。因此,近期的机会是透明和可追溯的临床决策支持,而不是自主的癌症诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JMIR Cancer
JMIR Cancer ONCOLOGY-
CiteScore
4.10
自引率
0.00%
发文量
64
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书